To play the media you will need to either update your browser to a recent version or update your Flash plugin.
GlaxoSmithKline officials have admitted that some of the pharmaceutical company’s top executives in China may have violated Chinese laws. Beijing has accused the company of engaging in a wide-ranging bribery scheme to boost sales and profits in the country. The company said it is cooperating with the investigation. Jim Zarroli